Navigation Links
Molecule responsible for age associated macular degeneration identified

CLEVELAND--A dart-like molecule that sticks to proteins in the eye is the main trigger for the unchecked growth of blood vessels, according to researchers at Case Western Reserve University and the Cleveland Clinic Cole Eye Institute. //Uncontrolled blood vessel growth is one of the main reasons for the development of age-related macular degeneration (AMD), the leading cause of blindness among people over 65 in the United States.

Robert Salomon and his graduate students Kutralanathan Renganathan and Liang Lu of Case's Department of Chemistry in the College of Arts and Sciences, found that the molecule, Carboxyethylpyrroles (CEPs), attaches to proteins found in the eye, triggering the uncontrolled growth of blood cells.

The Case researchers teamed up with Quteba Ebrahem Jonathan Sears, Amit Vasanji, John Crabb and Bela Anand-Apte and Xiaorong Gu (a Salomon group alumna), of Cleveland Clinic, to complete the study titled Carboxyethlpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration.'

The results of their collaborative work were published in the recent Proceedings of the National Academy of Science (PNAS).

AMD is a progressive disease that results in the severe loss of vision. The early stages of AMD are characterized as 'dry,' with the disease advancing to the 'wet form' as the retina, the part of the eye responsible for central vision, becomes infused with fluid from leaky new blood vessels, during a process called neovascularization. The unchecked blood vessel growth, or angiogenesis, in the retina accounts for 80% of the vision loss in the advanced stages of AMD.

The retina cells that detect light contain polyunsaturated fatty lipids that are exquisitely sensitive to damage by oxygen. Even in healthy eyes, these cells are renewed every ten days. The researchers at Case and Cleveland Clinic used a method developed by Salomon to specifical ly detect and measure the amount of CEPs found in the eye.

The researchers did in vivo animal studies with membranes from chicken eggs and rat eyes and found that CEPs attached to proteins induce angiogenesis. They also found that the protein part of CEP-protein adducts is not important for producing the growth of the blood vessels. Rather, the actual CEP is the cause of angiogenesis.

In an attempt to block CEP from triggering the angiogenesis process, 'we are now trying to find the receptors – the keyholes – in the retina cells that are activated by CEPs,' said Salomon. 'We are also designing drugs that can mop up the CEPs or prevent their formation.'

The research is supported by an Ohio Board of Regents Biomedical Research Technology Transfer Award to the Cole Eye Institute, National Institutes of Health Grants as well as the Foundation Fighting Blindness and the American Health Association.

For more than three decades, Salomon has worked in the area of lipid research. His work centers on the oxidation of lipids in the body that contributes to a host of diseases including glaucoma, keratitis and other eye diseases as well as Alzheimer's disease, atherosclerosis, autism and end-stage renal disease. He discovered many chemical transformations that occur as a result of lipid oxidation, and generated some of the first molecular tools that have been used in clinical studies relating the hardening of the arteries in heart disease. In the hope of preventing the formation of toxic molecules in the eye, through the combination of oxygen with lipids, Salomon is now studying the processes that generate them with a new grant from the National Eye Institute of the National Institutes of Health.



Source-Eurekalert
SA
'"/>




Related medicine news :

1. New Molecule that can stop the growth of Viruses
2. Puberty may be due to GPR54 gene and KiSS-1 Molecule
3. Molecule responsible for muscle repair identified
4. Molecule aids fight E. Coli Infections
5. Molecule That Aids Bacterial Infections Identified
6. Molecule Behind Multiple Sclerosis Discovered
7. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
8. Scientists Discover Prostate Cancer Triggering Molecule
9. Passion Fizzling Out? Blame The “Love Molecule
10. Sensor Can Detect "Unhealthy" Molecules In Breath
11. Polymer Molecule Layered On Carb Molecule to Increase Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: